Quince Therapeutics announced conditional resignations of CEO and CMO Dirk Thye and COO Brendan Hannah, effective two business days after the September 25, 2026 Special Meeting. These departures are contingent on stockholder approval of proposals to issue shares upon conversion of Series C Preferred Stock and exercise of warrants related to the Orphai acquisition and concurrent PIPE financing, which would represent over 20% of outstanding common stock under Nasdaq rules. The Board also approved conditional appointments of Brigette Roberts as CEO, John Militello as CFO, and Keith Fandrick as COO, all effective at the same time. Additionally, the Board reduced its size from five to four directors immediately upon Thye's resignation. Quince Therapeutics operates in the biotechnology industry, focusing on developing therapeutic treatments.
